Akesa Pharma’s extensive experience helps
you navigate through the complexities of
clinical trial procurement
Akesa Pharma was established to bridge the divide between demand and access for clinical trial medicines.
We source pharmaceutical medicines through an extensive global supply network, simplifying the procurement process for clients.
Akesa Pharma’s expertise is creating bespoke solutions in sourcing and procurement of commercial pharmaceuticals to meet specific clinical trial demands.
Our professional and detailed approach has made Akesa the partner of choice for pharmaceutical and biotech companies, clinical research organisations, research groups, hospitals and clinical manufacturing organisations.
Akesa Pharma specialises in procuring comparator products for clinical trials from international markets.
We have established relationships with pharmaceutical manufacturers and a large network of secure and validated suppliers across Australia, New Zealand, Asia-Pacific, Europe and the USA.
With an established network of couriers and logistics partners across the globe, Akesa Pharma can procure comparator products in country for your trial and manage delivery to sites through its clinical projects team.
Biosimilar research is becoming increasingly prevalent in the pharmaceutical industry and competition continues to grow daily.
Akesa Pharma has the expertise and relationships to source the correct innovator product for your trial. Our global network allows us to source these innovators from the international market. We tailor our service to find the right solution to ensure that the product you require arrives securely and on time.
Akesa Pharma understands the importance that analytical testing has on the initial stages of your trial and works with you to source the exact product required.
We can manage your multi-country, multi-batch with multi-expiry analytical sample request from a central or international market source.
Managing procurement for global trials can present a number of issues when particular products are required in multiple countries.
Identifying and securing product in the quantities required for each trial in each country can be challenging.
With our central sourcing strengths, we were able to source the required product quantities in each country and achieve the desired result for our client.
In 2015 a multinational pharmaceutical company came to Akesa Pharma looking to source comparator product, re-label both the comparator and their own product and distribute these products directly to more than 100 sites in eight different regions under strict temperature control.
By leveraging our secure and validated network, working closely with our contacts in each of the required territories, our clinical projects team delivered the product on time and maintained the high degree of quality required by the sponsor.
Akesa Pharma was able to identify, source, rework and deliver the exact product in each territory while maintaining rigorous timelines required for the sponsor.
Sourcing product for early phase biosimilar trials can be complex, difficult and compounded by regulatory constraints and logistical costs. By managing the process closely and working with a secure network, costs and risks can be minimized.
In early 2016 Akesa Pharma was approached by a small biotech company with a complex sourcing project. The sponsor required samples for analytical testing with multiple
strengths, multiple batches and expiries being sourced from multiple countries.
Using our relationship with the market authorization holder of the product we were able to procure more options that the sponsor required. Akesa then coordinated temperature controlled shipments from multiple locations to be delivered to two laboratories in two different countries.
The speed and efficiency of which this project was delivered allowed the sponsor to bring its project timelines forward. This translated into a direct cost saving later in the project.
If you happen to find yourself down Flinders Lane on a weekday, it’s worth taking a peek at building 141 – the Pawson House...more >
“Cutting edge biology can be an uncertain place for patients, investors and governments. But it can also be the door to success” In recent...more >
Near-sourcing should always be the first option. It saves money, improves efficiently and adds value to the local biopharma industry. There’s nothing not to...more >